Ventripoint Diagnostics Ltd. logo

Ventripoint Diagnostics Ltd. (5V7)

Market Closed
10 Dec, 20:00
XBER XBER
0. 06
+0
+5.22%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
0 Eps
0.06
Previous Close
Day Range
0.06 0.06
Year Range
0.04 0.12
Want to track 5V7 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

5V7 closed Wednesday higher at €0.06, an increase of 5.22% from Tuesday's close, completing a monthly increase of 9.01% or €0. Over the past 12 months, 5V7 stock lost -9.7%.
5V7 is not paying dividends to its shareholders.
The last earnings report, released on Nov 28, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Ventripoint Diagnostics Ltd. has completed 1 stock splits, with the recent split occurring on Dec 07, 2015.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on TSX-V (CAD).

5V7 Chart

Ventripoint Diagnostics Ltd. (5V7) FAQ

What is the stock price today?

The current price is €0.06.

On which exchange is it traded?

Ventripoint Diagnostics Ltd. is listed on TSX-V.

What is its stock symbol?

The ticker symbol is 5V7.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

Has Ventripoint Diagnostics Ltd. ever had a stock split?

Ventripoint Diagnostics Ltd. had 1 splits and the recent split was on Dec 07, 2015.

Ventripoint Diagnostics Ltd. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Dr. George Adams B.A.Sc., ICD.D., M.A.Sc., Ph.D. CEO
XBER Exchange
CA92281P2008 ISIN
US Country
- Employees
- Last Dividend
7 Dec 2015 Last Split
- IPO Date

Overview

Ventripoint Diagnostics Ltd. is a pioneering medical device company known for its innovative approach to the diagnosis and monitoring of heart disease. Established in 2005 and based in Toronto, Canada, the company has gained international recognition for its contributions to medical imaging technology. Ventripoint's mission focuses on enhancing patient care by providing healthcare professionals with advanced diagnostic tools that offer precise and accurate assessments of heart health. Their hallmark product, the Ventripoint Medical System (VMS), alongside the VMS+ software, represents a significant leap forward in cardiac imaging. These technologies allow for the creation of detailed three-dimensional heart models that give unprecedented insights into the heart's volume and function, supporting the management of a wide range of cardiac conditions.

Products and Services

  • Ventripoint Medical System (VMS): An innovative medical imaging system designed to transform two-dimensional cardiac ultrasound data into detailed three-dimensional models of the heart. It helps in assessing heart chamber volumes and functions, providing vital data for the accurate diagnosis and management of heart diseases.
  • This system is pivotal for clinicians who require precise heart measurements to determine the best course of treatment for their patients. By offering a more comprehensive view of heart health, VMS aids in the effective monitoring of patients with heart conditions.

  • VMS+ software: A cutting-edge software tool that works in conjunction with the VMS hardware, allowing for the creation of 3D models of the heart. This software enables the generation of accurate volumetric measurements of the heart's chambers, providing crucial insights into the heart's structure and function.
  • The VMS+ software enhances the VMS system's capabilities, facilitating an even deeper understanding of cardiac conditions through detailed heart modeling. It's an essential tool for healthcare providers looking to leverage technological advancements in the diagnosis and treatment of heart diseases.

  • Heart Disease Applications: Ventripoint is also developing a comprehensive suite of applications designed to address a broad spectrum of heart conditions. These include congenital heart disease, pulmonary hypertension, the cardiotoxic effects of chemotherapy treatments for cancer, and Covid-19 related heart problems.
  • With a focus on addressing the various manifestations of heart disease, these applications expand the utility of the VMS technology. They allow for tailored assessments and monitoring strategies, catering to the unique needs of patients suffering from specific heart-related health issues. This suite of applications exemplifies Ventripoint's commitment to advancing heart disease diagnosis and treatment through innovation.

Contact Information

Address: 18 Hook Avenue, Toronto, ON, Canada, M6P 1T4
Phone: 416-848-4156